Skip to main content

Fiscal Wizard · Single-issue tearsheet

GSK / Jun 22, 2026 Run #7564

GSK

GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Composite verdict

A 78.4 / 100
Bullish setup · Mean Reversion 10 drivers · 3 gates blocking
  • Connors RSI(2)
  • Double 7s
  • SuperTrend
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 3rd of 22 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 19 signals0% Bear
Momentum Bullish 81Mean-reversion Bullish 63

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -61%
Asset value $8.17Earnings power value $32.02Price $50.67

Priced above its no-growth earnings power value ($32.02/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

56.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Dividend Yield 82
Margin of Safety 0
Greenblatt ROC 81
Inventory Turnover 0
Asset Turnover 76
Cash Conversion Cycle 0

Technicals Bullish

99.9 / 100

Bullish setup leads (Connors RSI(2), Double 7s, SuperTrend); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Connors RSI(2) 86
Double 7s 86
SuperTrend 83

Risk Gates

3 blocking 6 caution

3 guards active, 22 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Altman Z-Score Caution

Bottom-band Altman Z blocks bullish signals — distress risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for GSK.